TruScreen Group (TRU) investor relations material

Opening remarks and agenda

• Meeting opened with a welcome to shareholders, both in-person and online, and introduction of the board and key executives.

• Apologies noted for absent director; voting procedures and agenda outlined, including CEO presentation, formal resolutions, and general business.

• Introduced TruScreen's AI-enabled cervical cancer screening device and outlined the meeting agenda, including technology overview, market landscape, sales strategy, and financial performance.

• Voting conducted by poll, with results declared post-meeting and lodged on NZX.

Board and executive committee updates

• Board refreshed with new directors; Christine Pears replaced Juliet Hull, and Chris Horn retired after 13 years.

• Rhys O'Connell introduced as a new director, bringing commercial and market expertise.

• Board composition adjusted for dual listing, with differential fee payments for NZ and Australian directors.

• Tony Ho (Non-Executive Chairman) and Marty Dillon (CEO) provided contact details and led the meeting.

Financial performance review

• FY26 annual sales reached NZ$2.4m, a 42% year-on-year increase.

• Total revenue for FY26 was NZ$2.8m, up 33% year-on-year.

• EBITDA remained unchanged at -NZ$2.2m; net assets increased 160% year-on-year.

• Market capitalization as of August 2026 was NZ$15.7m, with 1,047,718,877 shares on issue.

• NZ$5m capital was raised in June 2026 through oversubscribed placements and rights offers, strengthening financial position for 18 months.